The company can hold out without a partner and still advance their drugs in the lab the higher the price will be when they do partner their drugs. This is a three investment IMO. Don't let people dissuade you from you goals. There has been no bad news, and recent news was relatively good. Time and patience is what is needed. Will continue to follow this stock and give updates. Plan a calling their IR soon. Some dumbos who don't know anything and say the stock sucks without any validation are zzzzzz. t
Hey A1, worth about maybe 15 to 20 on a lotto pick. Average dose being used is 5 to 10mg when the FDA thought it would be about 40mg. Paying $239K for this drug.....I'd really feel guilty about taking the health care system for that much for so little. t
VICL in trouble if it can't keep up with the other DNA vaccine companies. Still down over 75% from highs on the year. Good thing, like sand-bagging in bowling. Soon the high for the year will be less than $1.30 and so in about a year you will be able to use your Putin strategy about talking how VICL is making new highs every week as it inches toward a buck forty. You should really look for a job in some communist goverment where you can spew out your BS to the people. t
The value goes up as you go through the evaluation process. Why give the drug away? Things IMO are going as expected. Going after CA as a disease has the highest risk of any biotech undertaking, save maybe Alzhemier disease. The stock is extremely cheap here. Three year target of $15 which is easily obtainable with success in the lab. t
Skeletal muscle homeostasis in Duchenne muscular dystrophy: modulating autophagy as a promising therapeutic strategy
Frontiers in Neurology, 07/17/2014 Review Article
De Palma C, et al. – The aim of this review is to describe and discuss the clinical relevance of the recent advances dissecting autophagy and its signalling pathway in Duchenne muscular dystrophy (DMD). The study suggest that at molecular levels, the Akt axis is one of the key disregulated pathways, although the molecular events are not completely understood.
Akt1-mediated fast/glycolytic skeletal muscle growth attenuates renal damage in experimental kidney disease
Journal of the American Society of Nephrology, 07/16/2014 Clinical Article
Hanatani S et al. – In this study, authors utilized a skeletal muscle–specific, inducible Akt1 transgenic (Akt1 TG) experimental model that promotes the growth of functional skeletal muscle independent of exercise to investigate the effects of muscle growth on kidney diseases. However, the data support the concept that loss of muscle mass during kidney disease can contribute to renal failure, and maintaining muscle mass may improve clinical outcome.
You're trying too hard. If the stock tanks and the company goes out of business.....then come back and kick everyone's #$%$. But the reality is this is how biotechs are. VRTX started back in 1989 as did SRPT, known as AVII. This company has huge risk, but also huge potential. Not an investment for everyone, and it appears especially not an investment for you. t
You are on the ISIS board which is a forum for ISIS and you are telling dutiful people here to scram......that is a reflection of your psychosis. Talk to your doctor about Lutuda.....a Zyprexa without the weight gain. Got to look out for even people like you. t
Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin(mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma
Cancer Treatment Reviews, 07/14/2014 Review Article Clinical Trial Below
Beck JT, et al. – This review will discuss therole of the PI3K/AKT/mTOR pathwayin cancer and how the discovery ofgenetic alterations in this pathway in patients with squamous cell lung carcinoma can inform the development of targeted therapies for this disease. An overview of ongoing clinical trials investigating PI3K/AKT/mTOR pathway inhibitorsinsquamous cell lung carcinoma will also be included.
I don't know how you can post that with a straight face. t
Down-regulation of miR-29c in human bladder cancer and the inhibition of proliferation in T24 cell via PI3K-AKT pathway
Medical Oncology, 07/11/2014
Fan YR, et al. – This study explored new tumor suppressor microRNA in bladder cancer and conducted a functional analysis of its suppressive role. It found that miR–29c could be an active player in the disease state and may be a promising tumor suppressor in bladder cancer.
Methods and Results
•To investigate the expression of miR–29c, qRT–PCR was used in 30 pairs of bladder cancer tissues and normal tissues (adjacent bladder tissue samples).
•The expression of miR–29c was down regulated in bladder cancer tissues compared with normal tissues.
•Low–level expression of miR–29c was associated with tumor stage (P=0.002), and ectopic over–expression of miR–29c in T24 cells can significantly inhibit cell proliferation, decrease motility, suppress the G1/S cell cycle transition and induce apoptosis.
•It could also cause a decrease in AKT and GSK–3β phosphorylation.
•While LY294002 reduced the protein level of pAKT, the over–expression of miR–29c can further decrease its level in T24 cells pretreated with LY294002.
•The proliferation inhibition of T24 may take place via AKT–GSK3β pathway.
Might be a head-fake:)) Earnings out by end of July. If no earnings.....why, if none, when? The higher your liver enzymes go the more risk of atrial fibrillation. No one can say what fatty infiltration of the small intestine will do long term. The biggest thing is that lipidologists are having problems with the liver enzymes going up so much. That is a surprise because the biggest problem that be holding the med down would be diarrhea. That is a big problem, but the liver enzyme thing, as was noted in their 23 patient study, where 3 patients developed rapid ascension of liver enzymes to 11 times normal and the FDA blew off is coming to fruition as a problem in real-life. Earnings at the end of July. If there are no earnings I anxiously await the CEO's newest explanation as to why they were missed, and I await his next purchases of the stock....which I do give him credit....he has purchased over 50K shares in the range of $32 to $34, maybe he can be more so people think that there is excellent insider buying as a good reason to own the stock. t
This biotech has held up relatively well given the circumstances for high beta stocks. I have followed this company for a number of years and believe that they recoiled, looked at their strengths and that when they came forward with the CA programs that they did it after careful consideration and research. I would be very wary to short this stock from what I know about their drugs and their potential. Will call the IR people soon and report here. t
Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K–Akt oncogenic dependence in pancreatic ductal adenocarcinoma
Clinical Cancer Research, 07/10/2014 Exclusive Author Commentary Clinical Article
Wong MH, et al. – The hypothesis of this study is that PI3K and EGFR coinhibition may be effective in PDAC with upregulated PI3K–Akt signaling. PDAC with increased expression of the PI3K–Akt pathway was susceptible to PI3K–EGFR coinhibition, suggesting oncogenic dependence.
Ross C. Smith (07/10/2014) comments:
Following View Author Commentary page
We demonstrated that when pancreatic cancer cells were under the influence of the EGFR inhibitor, erlotinib, there was increased expression of the PI3K/Akt/mTOR proteins indicatiing that this pathway became constituatively active. This indicated that pancreatic cancer became dependent on the PI3K pathway under the influence of erlotinib. Dual blockade with erlotinib and BYL-719, a novel selective class I PI3K inhibitor, were shown to be synergistic in cell line studies and to inhibit the growth of primary pancreatic cancer tissue in xenograft models where it was associated with increased apoptosis. This combination should be tested in a Phase I/II trial in humans with pancreatic cancer.
Agenus (AGEN) is higher by 17% this morning. The company announced final results from a single-arm, multi-institutional, open-label, Phase 2 study showing that patients with newly diagnosed glioblastoma multiforme (GBM) who received Agenus' Prophage autologous cancer vaccine added to the standard of care treatment, lived nearly twice as long as expected. In this Phase 2 study, 50% of the patients lived for two years, an encouraging result for a cancer that often kills patients within one year. Prophage patients demonstrated a median overall survival of approximately 24 months and 33% of patients remain alive at 2 years and continue to be followed for survival. In addition to the long-term survival data, vaccine treated patients had a median progression-free survival (PFS) of nearly 18 months, approximately two to three-times longer than patients treated with radiation and temozolomide alone. Importantly, 22% of patients were alive and without progression at 24 months and continue to be followed for survival.
With guidance of maybe the worst CEO in all of biotech, upon comparing apples and apples this company is a big zero and one more failure away from BK. Don't believe me about the poor potential and poor performance.....just go the actual board and see what actual investors think about their results so far and what they are looking for in the future.........it isn't an GPRO board that's for sure. t
You're about 20 cents above the high for the year in a market that has been in a four or five year bull market. So you yourself have been participating because you have the bull, but VICL doesn't have the market. In fact, another CART announcement by another company. AGEN is going to kick VICL's tail in regards to virology, and the biotechs in CART are going to kick VICL's tail there. Keep touting it and the VNN will keep you informed of the truth. t
Come on, this is the day of GOOG.......look it up. The fact that you even ask that question again shows your danger to anyone who would take you seriously as a "vaccine expert" giving out information to the masses. If I were you I would have secretly looked it up and not have ask that question in this forum. VICL, maybe the biggesst nonperformer in this five year bull market, with maybe the biggest danger to become the next APPY. t